Luciferase Reporter Cell Line - SGC7901

SGC-7901 cells are a human gastric adenocarcinoma–derived cell line widely used as an in vitro model for studying gastric cancer biology and tumor progression of the digestive system. These cells are characterized by epithelial-like morphology, high proliferative capacity, and genetic alterations commonly associated with poorly differentiated gastric carcinoma. SGC-7901 cells exhibit dysregulated signaling pathways involved in cell proliferation, apoptosis resistance, invasion, and epithelial–mesenchymal transition (EMT), making them suitable for investigating mechanisms underlying gastric tumor growth and metastasis. The Luciferase Reporter Cell Line – SGC-7901 is generated by stable integration of a luciferase reporter construct driven by pathway-responsive elements or transcription factor–specific promoters into the parental SGC-7901 background, enabling real-time and quantitative monitoring of transcriptional and signaling activities while preserving the intrinsic biological properties of the original gastric cancer cell line.

The Luciferase Reporter Cell Line – SGC-7901 is widely applied in gastric cancer research, oncogenic signaling studies, and anti-tumor drug screening. It is particularly useful for evaluating key pathways implicated in gastric carcinoma progression, including PI3K/AKT/mTOR, MAPK/ERK, NF-κB, Wnt/β-catenin, and TGF-β/SMAD signaling, which are closely associated with tumor growth, metastasis, and therapy resistance. The luciferase reporter system provides a sensitive and reliable quantitative readout for assessing pathway activation or inhibition in response to pharmacological compounds, biologics, or genetic modulation. This model is commonly used in high-throughput screening of anti-gastric cancer agents, as well as in mechanistic studies of tumor invasion, angiogenesis, and apoptotic regulation. Its stability, reproducibility, and strong signal sensitivity make it a valuable platform for both basic research and preclinical evaluation of targeted therapies for gastric cancer.